A comparative study of CSF neurofilament light and heavy chain protein in MS
- 25 March 2013
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 19 (12), 1597-1603
- https://doi.org/10.1177/1352458513482374
Abstract
Background: There is a lack of reliable biomarkers of axonal degeneration. Neurofilaments are promising candidates to fulfil this task. We compared two highly sensitive assays to measure two subunits of the neurofilament protein (neurofilament light (NfL) and neurofilament heavy chain (NfH)). Methods: We evaluated the analytical and clinical performance of the UmanDiagnostics NF-light® enzyme-linked immunosorbent assay (ELISA) in the cerebrospinal fluid (CSF) of a group of 148 patients with clinically isolated syndrome (CIS) or multiple sclerosis (MS), and 72 controls. We compared our results with referring levels of our previously-developed CSF NfHSMI35 assay. Results: Exposure to room temperature (up to 8 days) or repetitive thawing (up to 4 thaws) did not influence measurement of NfL concentrations. Values of NfL were higher in all disease stages of CIS/MS, in comparison to controls ( p ≤ 0.001). NfL levels correlated with the Expanded Disability Status Scale (EDSS) score in patients with relapsing disease ( rs = 0.31; p = 0.002), spinal cord relapses and with CSF markers of acute inflammation. The ability of NfL to distinguish patients from controls was greater than that of NfHSMI35 in both CIS patients ( p = 0.001) and all MS stages grouped together ( p = 0.035). Conclusions: NfL proved to be a stable protein, an important prerequisite for a reliable biomarker, and the NF-light® ELISA performed better in discriminating patients from controls, compared with the ECL-NfHSMI35 immunoassay. We confirmed and expanded upon previous findings regarding neurofilaments as quantitative markers of neurodegeneration. Our results further support the role of neurofilaments as a potential surrogate measure for neuroprotective treatment in MS studies.Keywords
This publication has 34 references indexed in Scilit:
- Neurofilaments as biomarkers in multiple sclerosisMultiple Sclerosis Journal, 2012
- Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and lossJournal of the Neurological Sciences, 2005
- Biological markers in CSF and blood for axonal degeneration in multiple sclerosisThe Lancet Neurology, 2005
- Monoclonal Antibodies Selective for Low Molecular Weight NeurofilamentsHybridoma and Hybridomics, 2002
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- Neuronal Intermediate FilamentsAnnual Review of Neuroscience, 1996
- The rod domain of NF-L determines neurofilament architecture, whereas the end domains specify filament assembly and network formation.The Journal of cell biology, 1993
- Neurofilaments are obligate heteropolymers in vivoThe Journal of cell biology, 1993
- Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cellsCell, 1992
- Self-assembly in vitro of the 68,000 molecular weight component of the mammalian neurofilament triplet proteins into intermediate-sized filamentsJournal of Molecular Biology, 1981